Evidence map›Paper›PMID 36995085›Full record

ArticleBlood advances2023

Unraveling the genetics of transformed splenic marginal zone lymphoma.

Marta Grau, Cristina López, Alba Navarro, Gerard Frigola, Ferran Nadeu, Guillem Clot, Gabriela Bastidas-Mora, Miguel Alcoceba, Maria Joao Baptista, Margarita Blanes and 17 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. [The guideline for the diagnosis and treatment of marginal zone lymphoma in China (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
    Guideline
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Haematologica · 2024
    Article
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 12 institutions in 2 countries.

Marta GrauMolecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.ORCID 0000-0003-3779-0387
Cristina LópezMolecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Alba NavarroMolecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Gerard FrigolaHematopathology Section, Department of Pathology, Hospital Clínic de Barcelona, Barcelona, Spain.ORCID 0000-0001-6794-6456
Ferran NadeuMolecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.ORCID 0000-0003-2910-9440
Guillem ClotMolecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.ORCID 0000-0003-2588-7413
Gabriela Bastidas-MoraDepartment of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain.
Miguel AlcocebaCentro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
Maria Joao BaptistaDepartment of Hematology, Institut Català d'Oncologia-Hospital Germans Trias i Pujol-Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Margarita BlanesDepartment of Hematology, Hospital General Universitario de Elda, Alicante, Spain.
Dolors ColomerMolecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Dolors CostaMolecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Eva Domingo-DomènechDepartment of Hematology, Institut Català d'Oncologia, Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0001-8907-090X
Anna EnjuanesCentro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
Lourdes EscodaDepartment of Hematology, Institut Català d'Oncologia -Hospital Joan XXIII, Tarragona, Spain.
Pilar ForcadaDepartment of Hematology, Hospital Universitari Mútua Terrassa, Terrassa, Spain.
Eva GinéMolecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Mónica Lopez-GuerraMolecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Olga RamónDepartment of Hematology, Hospital General de Igualada, Igualada, Spain.
Alfredo Rivas-DelgadoMolecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.ORCID 0000-0003-0385-3415
Laura Vicente FolchDepartment of Hematology, Consorci Sanitari de Terrassa, Terrassa, Spain.
Andrew WotherspoonDepartment of Histopathology, Royal Marsden NHS Foundation Trust, London, United Kingdom.
Fina ClimentDepartment of Pathology, Hospital Universitari de Bellvitge-Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0002-4360-8388
Elias CampoMolecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.ORCID 0000-0001-9850-9793
Armando López-GuillermoUniversitat de Barcelona, Spain.
Estella MatutesDepartment of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain.
Sílvia BeàMolecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.ORCID 0000-0001-7192-2385
Hospital Clínic de Barcelona · ESFundació Clínic per a la Recerca Biomèdica · ESBellvitge University Hospital · ESConsorci Sanitari de Terrassa · ESHospital d'Igualada · ESHospital General de Elda · ESInstitut Català d'Oncologia · ESInstitut d'Investigació Biomédica de Bellvitge · ESJosep Carreras Leukaemia Research Institute · ESMútua Terrassa · ESRoyal Marsden NHS Foundation Trust · GBUniversidad de Salamanca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The genetic mechanisms associated with splenic marginal zone lymphoma (SMZL) transformation are not well defined. We studied 41 patients with SMZL that eventually underwent large B-cell lymphoma transformation. Tumor material was obtained either only at diagnosis (9 patients), at diagnosis and transformation (18 patients), and only at transformation (14 patients). Samples were categorized in 2 groups: (1) at diagnosis (SMZL, n = 27 samples), and (2) at transformation (SMZL-T, n = 32 samples). Using copy number arrays and a next-generation sequencing custom panel, we identified that the main genomic alterations in SMZL-T involved TNFAIP3, KMT2D, TP53, ARID1A, KLF2, 1q gains, and losses of 9p21.3 (CDKN2A/B) and 7q31-q32. Compared with SMZL, SMZL-T had higher genomic complexity, and higher incidence of TNFAIP3 and TP53 alterations, 9p21.3 (CDKN2A/B) losses, and 6p gains. SMZL and SMZL-T clones arose by divergent evolution from a common altered precursor cell that acquired different genetic alterations in virtually all evaluable cases (92%, 12 of 13 cases). Using whole-genome sequencing of diagnostic and transformation samples in 1 patient, we observed that the SMZL-T sample carried more genomic aberrations than the diagnostic sample, identified a translocation t(14;19)(q32;q13) present in both samples, and detected a focal B2M deletion due to chromothripsis acquired at transformation. Survival analysis showed that KLF2 mutations, complex karyotype, and International Prognostic Index score at transformation were predictive of a shorter survival from transformation (P = .001; P = .042; and P = .007; respectively). In summary, SMZL-T are characterized by higher genomic complexity than SMZL, and characteristic genomic alterations that could represent key players in the transformation event.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, DiffuseSplenic NeoplasmsHumansMutationTranslocation, Genetic

Identifiers

PMID36995085
PMCPMC10368783
OpenAlexW4361279314

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.